Physician profile
James Riley Davis
NPI 1134786528
$2,469.97
in general payments reported to CMS, 2019-2025
15 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $170 · 2023: $383 · 2024: $875 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,299.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $814.32 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $404.04 | 2022-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $367.06 | 2023-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $180.28 | 2025 | Jornay Pm |
| Pfizer INC. | $159.50 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $119.92 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $112.45 | 2024-2025 | Gardasil 9, Enflonsia, Rotateq |
| Tris Pharma INC | $90.33 | 2024-2025 | Dyanavel Xr |
| Seqirus USA INC | $43.39 | 2025 | Flucelvax |
| Organon LLC | $38.50 | 2022 | |
| Glaxosmithkline, LLC. | $36.35 | 2023-2025 | Bexsero, Penmenvy |
| Vertical Pharmaceuticals, LLC | $34.84 | 2024 | Relexxii |
| Cranial Technologies, INC | $31.06 | 2024 | Doc Band |
| Acadia Pharmaceuticals INC | $23.36 | 2025 | Daybue |
| Kowa Pharmaceuticals America, INC. | $14.57 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.